Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis (Q24791960)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Meta-analysis in clinical trials

7 April 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

7 April 2017

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Should unpublished data be included in meta-analyses? Current convictions and controversies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Adverse reactions to contrast media: factors that determine the cost of treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Why sources of heterogeneity in meta-analysis should be investigated

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Identifying relevant studies for systematic reviews

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Hospital-acquired renal insufficiency: a prospective study

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Assessing the Quality of Randomised Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Assessing the Quality of Reports of Systematic Reviews: The QUOROM Statement Compared to Other Tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine and contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Acetylcysteine for prevention of contrast nephropathy: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Significant statistical heterogeneity in a meta-analysis of the usefulness of acetylcysteine for prevention of contrast nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Determinants of serum creatinine trajectory in acute contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Poor long-term survival after coronary angiography in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=526263

Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors

28 November 2018

1 reference

12 December 2020

The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency

1 reference

12 December 2020

Acetylcysteine and renal function following coronary angiographic procedures

1 reference

12 December 2020

Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study

1 reference

12 December 2020

Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study

1 reference

12 December 2020

Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction

1 reference

12 December 2020

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor

1 reference

12 December 2020

The effect of acute renal failure on mortality. A cohort analysis

1 reference

12 December 2020

N-acetyl cysteine ameliorates ischemic renal failure

1 reference

12 December 2020

1 reference

12 December 2020

Cytotoxic properties of salivary oxidants

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-2-38

7 January 2021